Axsome Therapeutics Inc
Statements
Cash Flow
Axsome Therapeutics Inc (AXSM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -33 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.8 | -7.2 | -6.6 | -7.1 | -6.4 | -6.3 | -6.7 | -7.7 | -5.9 | -9.8 | -9.5 | -8.7 | -11 | -18 | -23 | -19 | -16 | -21 | -27 | -25 | -27 | -29 | -33 | -34 | -23 | -28 | -5.8 | -55 | -54 | -30 | -53 | -30 | -19 | -26 | -43 | -32 | 1.0 | -19 | -21 | -33 | -71 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 1.3 | 2.0 | 2.0 | 2.0 | 1.4 | 1.7 | 1.7 | 1.8 | 2.0 | 2.1 | 2.1 | 1.7 | 1.7 | 2.4 | 2.3 | 2.4 | 1.1 | 8.1 | |
| 0.5 | 0.4 | 0.7 | 0.5 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 1.3 | 0.9 | 1.2 | 2.8 | 2.1 | 4.1 | 2.9 | 5.6 | 3.7 | 5.5 | 5.7 | 5.9 | 7.6 | 10 | 9.2 | 11 | 13 | 16 | 15 | 19 | 20 | 21 | 22 | 22 | 23 | 25 | 23 | 23 | 23 | 27 | 96 | |
| 0.5 | 2.1 | 0.7 | 0.5 | 0.4 | 3.2 | -2.1 | 0.5 | 0.4 | 0.3 | 1.3 | 0.9 | 1.2 | 2.8 | 2.1 | 4.1 | 4.1 | 5.6 | 3.7 | 5.1 | 5.7 | 5.9 | 7.6 | 10 | 9.2 | 15 | 13 | 16 | 15 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.9 | -0.4 | 0.6 | -0.6 | -0.5 | -0.2 | 0.1 | 0.0 | 1.9 | -0.5 | -0.2 | 4.0 | 7.2 | 4.2 | -0.3 | -4.9 | 2.9 | 2.6 | -2.0 | 1.2 | 2.1 | -1.0 | -0.9 | -2.9 | 11 | 17 | -9.6 | -13 | -9.0 | 3.4 | -6.8 | 23 | -16 | 13 | -10 | -14 | 8.8 | -6.8 | 17 | -11 | 7.8 | |
| 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.3 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.4 | 0.0 | 0.1 | 0.1 | 0.2 | 0.0 | 0.3 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | |
| -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -32,696 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | -307,549 | -0.2 | -53 | -0.1 | -0.2 | -0.1 | -0.1 | -0.4 | 0.0 | -0.1 | -0.1 | -0.1 | 0.0 | -0.3 | 0.0 | -0.1 | -0.1 | -0.1 | -0.5 | -0.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.3 | 0.2 | 53 | 29 | 1.2 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 15 | 0.1 | 0.1 | 24 | 0.1 | 2.2 | 1.6 | 9.4 | 25 | 20 | 0.5 | 194 | 0.6 | 12 | – | 2.1 | 8.0 | -0.1 | 0.4 | -0.1 | -0.1 | 0.0 | -0.3 | -0.2 | -0.9 | -0.3 | -0.4 | -0.3 | -1.6 | -1.3 | 2.9 | – | – | – | – | – | – | – | – | |
| – | 10 | -0.3 | -0.3 | -0.3 | -0.3 | -0.8 | -0.8 | -0.8 | -0.9 | 13 | – | – | 28 | 28 | 28 | 28 | – | – | – | 45 | -0.3 | 45 | 45 | 30 | 30 | 54 | 30 | – | – | – | – | -0.3 | -0.3 | -0.4 | -2.5 | -0.7 | -0.5 | -0.7 | -1.2 | -3.1 | |
| 0.0 | 10.0 | 15 | 0.1 | 0.1 | 8.6 | -0.7 | 1.4 | 0.8 | 8.5 | 38 | 20 | 0.5 | 194 | 0.6 | 12 | 27 | 2.1 | 8.0 | 2.0 | 0.4 | 0.7 | 31 | 75 | 177 | 1.1 | 52 | 246 | 33 | 0.0 | -1.2 | 14 | 30 | 14 | 29 | 35 | 21 | 16 | 3.0 | 48 | 89 | |
| -4.9 | 2.7 | 8.4 | -7.0 | -6.3 | 2.3 | -7.4 | -6.3 | -5.1 | -1.3 | 29 | 11 | -10 | 176 | -23 | -6.6 | 12 | -18 | -19 | -23 | -27 | -28 | -1.8 | -11 | 154 | -27 | 46 | 191 | -21 | -30 | -55 | -16 | 12 | -12 | -14 | 2.1 | 22 | -2.3 | -18 | 15 | 17 | |
| -4.9 | -7.2 | -6.6 | -7.1 | -6.5 | -6.3 | -6.7 | -7.7 | -5.9 | -9.8 | -9.5 | -8.7 | -11 | -18 | -23 | -19 | -16 | -21 | -27 | -25 | -27 | -29 | -33 | -34 | -23 | -28 | -5.9 | -55 | -54 | -30 | -54 | -30 | -18 | -26 | -44 | -32 | 1.0 | -19 | -21 | -33 | -71 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.